Sawada, Yoshikazu
Dr. Yoshikazu Sawada joined Dr. Elena Aikawa’s group at Center for Interdisciplinary Cardiovascular Sciences (CICS) in April 2019. He is currently working to identify novel therapeutic targets of cardiovascular calcification. After graduating from Osaka University, he entered Kowa Company Ltd. and was assigned to the Xenobiotics department at Tokyo New Drug Research Laboratories at 2010. In 2018, he obtained his Ph.D. from Tsukuba University in the lab of Prof. Hitoshi Shimano. There, he studied a new mechanism of sodium-glucose co-transporter2 (SGLT2) inhibitor, Tofogliflozin. After obtaining his Ph.D., he was assigned to the Pharmaceutical Division at Tokyo New Drug Research Laboratories and contributed to the development of a new antipsychotic.